Special Issue

The Evidence Base for Treatment of Tickborne Infections

Message from the Guest Editors

There needs to be a review of the different tickborne infections in 'immunocompetent hosts' and a review of the clinical manifestations and treatment options. For example, babesia is only described as a problem with splenectomised patients, but there is a wide spectrum of disease in immunocompetent hosts. And the issue of treatment of these infections needs to be analysed and summarised. While a short course of antibiotic treatment may work for early diagnosed infections. sometimes patients need longer course treatment, just like for other infections. For example, early diagnosed Coxiella burnetti infection caught early requires only short course antibiotic treatment. However late diagnosed infection with Coxiella requires longer treatment. This Special Issue aims to review these issues, and look at special populations who are infected with tickborne infections: immunocompetent, immunosuppressed, and special issues that arise in pregnancy and children. We hope to publish a collection of excellent papers on this topic, some review articles and some original studies. Keywords: Tickborne infections; Lyme disease; Co-infections

Guest Editors

Dr. John Lambert

Department of Infectious Diseases, University College Dublin, Dublin, Ireland

Dr. Brendan O Kelly

Department of Infectious Diseases, University College Dublin, Dublin, Ireland

Deadline for manuscript submissions

closed (30 April 2021)



an Open Access Journal by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/44441

Antibiotics

MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 7.3 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

